Peters plus syndrome mutations disrupt a noncanonical ER quality-control mechanism.
about
miRNA proxy approach reveals hidden functions of glycosylationThrombospondin-1-Based Antiangiogenic Therapy.Impaired ADAMTS9 secretion: A potential mechanism for eye defects in Peters Plus Syndrome.Unusual life cycle and impact on microfibril assembly of ADAMTS17, a secreted metalloprotease mutated in genetic eye disease.The multiple roles of epidermal growth factor repeat O-glycans in animal development.Genetic and biochemical evidence that gastrulation defects in Pofut2 mutants result from defects in ADAMTS9 secretion.Biological roles of glycans.Biological functions of fucose in mammals.Cardiac complications of congenital disorders of glycosylation (CDG): a systematic review of the literature.A proactive role of water molecules in acceptor recognition by protein O-fucosyltransferase 2.Functional characterization of zebrafish orthologs of the human Beta 3-Glucosyltransferase B3GLCT gene mutated in Peters Plus Syndrome.A sweet development in Notch regulation.O-Glycosylation modulates the stability of epidermal growth factor-like repeats and thereby regulates Notch trafficking.Protein O-fucosylation in Plasmodium falciparum ensures efficient infection of mosquito and vertebrate hosts.Distinct C-mannosylation of netrin receptor thrombospondin type 1 repeats by mammalian DPY19L1 and DPY19L3.Defective B3GALTL causes Peters-plus syndrome (PpS)Altered fucosyltransferase expression in the superior temporal gyrus of elderly patients with schizophrenia.Variant in human POFUT1 reduces enzymatic activity and likely causes a recessive microcephaly, global developmental delay with cardiac and vascular features.Apicomplexan C-Mannosyltransferases Modify Thrombospondin Type I-Containing Adhesins of the TRAP Family.Defective B3GALTL does not transfer glucose to O-fucosyl-proteinsB3GALTL transfers glucose to O-fucosyl-proteins
P2860
Q35740441-0C4D1978-F6B9-49B5-B782-58EC1B99DB92Q36417463-9E03FD4C-09D6-4063-B8A2-A2AE7664D740Q37298462-63A17355-68C2-4B60-85EE-68CB79B25914Q37630738-A2A4270D-B7A0-42E4-9624-15278D629514Q38547337-CD8EED3D-BE32-4A37-B2B5-486EE005F75AQ38764647-FF29A086-B293-41BF-99B8-19D89574BE53Q38936714-E4AE4F36-DBAC-449E-994B-B8050B0CD06DQ39254939-F6D2D2E1-48A2-4410-B57C-7D9C5DD8F8D1Q39446939-1B1A1D97-FC66-4C87-A3CF-6266689FE544Q40015515-77B6D906-061C-4C69-8E4D-E4B068CBED17Q41677280-792B30E9-ED94-4F3F-9641-EC1EC7115661Q41685382-E80D382D-8E74-4C5B-A37B-075FF10AC55FQ41685413-A5818BC4-CDB5-4630-ABAD-001D7F0C48EFQ41701401-21C86FCA-CF67-4CAB-BA36-60335B628AEBQ42316832-D8B0CF9D-FE5F-47C5-931A-327C2253A902Q45316552-0827AAAE-E175-4326-9232-F422322707EFQ48463317-EC9785E8-5651-4BD0-B1ED-8A1A82EDBE49Q49922672-C5FC2A60-82D4-4E51-BC2C-5104EB02DB44Q50061912-5D5F3867-94FB-44E2-8D6F-5981A9643E93Q50289232-F390BFC3-6B7C-488F-9CF7-42F3EE656F4EQ50296353-DD71A947-99FA-4A49-80DF-6C10BE41D4EF
P2860
Peters plus syndrome mutations disrupt a noncanonical ER quality-control mechanism.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Peters plus syndrome mutations disrupt a noncanonical ER quality-control mechanism.
@en
Peters plus syndrome mutations disrupt a noncanonical ER quality-control mechanism.
@nl
type
label
Peters plus syndrome mutations disrupt a noncanonical ER quality-control mechanism.
@en
Peters plus syndrome mutations disrupt a noncanonical ER quality-control mechanism.
@nl
prefLabel
Peters plus syndrome mutations disrupt a noncanonical ER quality-control mechanism.
@en
Peters plus syndrome mutations disrupt a noncanonical ER quality-control mechanism.
@nl
P2093
P2860
P921
P1433
P1476
Peters plus syndrome mutations disrupt a noncanonical ER quality-control mechanism.
@en
P2093
Elaine Majerus
Hideyuki Takeuchi
Robert S Haltiwanger
Sumreet Singh Johar
P2860
P304
P356
10.1016/J.CUB.2014.11.049
P407
P577
2014-12-24T00:00:00Z